
Jan 14 (Reuters) - Johnson & Johnson JNJ.N:
TECVAYLI® MONOTHERAPY DEMONSTRATES SUPERIOR PROGRESSION-FREE AND OVERALL SURVIVAL VERSUS STANDARD OF CARE AS EARLY AS FIRST RELAPSE IN PATIENTS WITH MULTIPLE MYELOMA PREDOMINANTLY REFRACTORY TO ANTI-CD38 THERAPY AND LENALIDOMIDE
J&J - 71% REDUCTION IN DISEASE PROGRESSION RISK AND 40% REDUCTION IN DEATH RISK
J&J - TECVAYLI MONOTHERAPY SAFETY PROFILE MANAGEABLE WITH NO NEW CONCERNS